David Wohl, MD
Co-director, UNC Regional Special Pathogen Treatment Center
Co-Director, UNC Project-Liberia
Co-director, UNC Global Clinical Trials Unit
CTU Site Leader, CRS Chapel Hill
Professor of Medicine, Division of Infectious Diseases
Areas of Interest
Optimizing HIV clinical management Emerging pathogen detection, Prevention, and Treatment
About
Dr. Wohl is a physician-clinical researcher and clinician with a career dedicated to the study and treatment of emerging infectious diseases. Prior to 2014, his clinical and research activities were almost exclusively focused on the care of people with HIV infection and HIV-related patient-oriented research. He leads a large NIAID-supported HIV Clinical Research Site (CRS) at UNC-Chapel Hill and serves as Co-PI for the UNC Global Clinical Trials Research Unit (CTU), which includes sites in North Carolina, Malawi, and Vietnam. With the Ebola virus disease outbreak in West Africa in 2014, he expanded his work to other emerging infectious diseases including Ebola and Lassa fever, and with the pandemic, SARS-CoV-2. Dr. Wohl’s interest in viral hemorrhagic fevers led to his co-founding and co-directing the UNC Project-Liberia and the establishment of its two productive research sites in this West African nation.
In the news
The UNC Institute for Global Health and Infectious Diseases is now enrolling participants in a fast-track trial of an oral COVID-19 treatment known as Bemnifosbuvir (BEM). Currently, Paxlovid is used for treating COVID-19. However, it is known to interact with common drugs that treat cholesterol, blood clots, and other conditions. Because of these side effects, … Read more Eli Lilly today released results of a clinical trial that found bamlanivimab, a monoclonal antibody, significantly reduced the risk of contracting COVID-19 among residents and staff of long-term care facilities. The Phase 3 trial was conducted in partnership with the NIH’s National Institute of Allergy and Infectious Diseases and the COVID-19 Prevention Network (CoVPN). … Read more ACTG names second new award for former UNC neurology professor, Kevin Robertson The national AIDS Clinical Trials Group expanded its annual recognition program in 2020 with two new awards named for University of North Carolina faculty members who died in 2019: Charles van der Horst, MD, an infectious diseases physician and researcher, and Kevin Robertson, … Read more It’s hot (especially wearing full PPE), it’s tedious, and it’s critical. A volunteer team of UNC infectious diseases faculty members along with UNC hospitalists has been conducting drive-up testing for COVID-19 in Sanford, NC, about 35 miles south of Chapel Hill, twice a month since June, seeing roughly 1,000 local residents so far this … Read more
New Study Seeks to Enroll Covid+ Individuals For Fast Track Trial of Oral COVID-19 Treatment
UNC investigators help prove a monoclonal antibody prevents, treats COVID-19 in nursing homes
ACTG honors David Wohl, MD, with first Charles van der Horst Humanitarian Award
ID faculty organize, conduct COVID-19 testing in hard-hit Lee County, NC
Education
-
Undergraduate
Boston University
-
Medical School
Robert Wood Johnson Rutgers Medical School
-
Residency
Duke University
-
Fellowship
University of North Carolina at Chapel Hill